Gracell Biotechnologies
About:
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer.
Website: https://www.gracellbio.com
Top Investors: Wellington Management, RA Capital Management, OrbiMed, Janus Henderson Investors, Vivo Capital
Description:
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.
Total Funding Amount:
$285M
Estimated Revenue Range:
$100M to $500M
Headquarters Location:
Suzhou, Jiangsu, China
Founded Date:
2017-01-01
Founders:
Wei William Cao
Number of Employees:
251-500
Last Funding Date:
2023-08-07
IPO Status:
Public
Industries:
© 2025 bioDAO.ai